Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 110, Issue 3, Pages 232-240
Publisher
Oxford University Press (OUP)
Online
2017-08-10
DOI
10.1093/jnci/djx179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?
- (2016) Roger P. A’Hern JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials
- (2016) Ludovic Trinquart et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- Neratinib after trastuzumab in patients with HER2-positive breast cancer
- (2016) Takahiro Hasegawa et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Arlene Chan et al. LANCET ONCOLOGY
- An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
- (2016) Julien Péron et al. Oncotarget
- The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials
- (2016) Julien Péron et al. JAMA Oncology
- Describing Differences in Survival Curves
- (2016) Rick Chappell et al. JAMA Oncology
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer
- (2015) J Péron et al. BRITISH JOURNAL OF CANCER
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Individualizing treatment choices using quantitative methods
- (2014) Stuart J. Pocock et al. AMERICAN HEART JOURNAL
- Evidence-Based Risk Communication
- (2014) Daniella A. Zipkin et al. ANNALS OF INTERNAL MEDICINE
- Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
- (2014) A. F. Sobrero et al. CLINICAL CANCER RESEARCH
- Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer
- (2014) Michael Coory et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis
- (2014) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect
- (2014) Patrick Royston et al. Trials
- Bias and Sensitivity Analysis When Estimating Treatment Effects from the Cox Model with Omitted Covariates
- (2013) Nan Xuan Lin et al. BIOMETRICS
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods
- (2012) B. Seruga et al. ANNALS OF ONCOLOGY
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Hazard ratios in cancer clinical trials—a primer
- (2012) Krastan B. Blagoev et al. Nature Reviews Clinical Oncology
- The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
- (2011) S. J. Pocock et al. EUROPEAN HEART JOURNAL
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
- (2010) Everardo D. Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- How Long Have I Got? Estimating Typical, Best-Case, and Worst-Case Scenarios for Patients Starting First-Line Chemotherapy for Metastatic Breast Cancer: A Systematic Review of Recent Randomized Trials
- (2010) Belinda E. Kiely et al. JOURNAL OF CLINICAL ONCOLOGY
- When Are "Positive" Clinical Trials in Oncology Truly Positive?
- (2010) A. Ocana et al. JNCI-Journal of the National Cancer Institute
- Review of Ongoing Clinical Trials in Non-small Cell Lung Cancer: A Status Report for 2009 from the ClinicalTrials.gov Website
- (2010) Janakiraman Subramanian et al. Journal of Thoracic Oncology
- Generalized pairwise comparisons of prioritized outcomes in the two-sample problem
- (2010) Marc Buyse STATISTICS IN MEDICINE
- The Hazards of Hazard Ratios
- (2009) Miguel A. Hernán EPIDEMIOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reformulating the hazard ratio to enhance communication with clinical investigators
- (2008) Marc Buyse Clinical Trials
- Reformulating the hazard ratio to enhance communication with clinical investigators
- (2008) Barry K Moser et al. Clinical Trials
- Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
- (2008) Leonard B. Saltz JOURNAL OF CLINICAL ONCOLOGY
- Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots
- (2008) P. Royston et al. JNCI-Journal of the National Cancer Institute
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started